To read the full story, subscribe or sign in.

OncoGenex Gains 75 Percent on OGX-011 Phase II Prostate Data

Dec. 4, 2008

Shares of OncoGenex Pharmaceuticals Inc. soared 75.6 percent on Wednesday thanks to positive survival data from a Phase II trial of lead compound OGX-011 in the first-line treatment of hormone refractory prostate cancer (HRPC). (BioWorld Today)

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for Jan 13, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 13, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Science in 2025: the best of the rest

BioWorld Science

A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.

LINC01116 has prognostic value in lung cancer, study shows

BioWorld MedTech

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...